Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neurovascular Market's Time Has Come: Stealthy Sequent Medical Unveils Strategy

This article was originally published in Start Up

Executive Summary

With foresight, good timing, or simply years of experience, the founders of Sequent Medical (who also founded MicroVention) are launching a new endovascular product in Europe just as large companies are signalling their interest in the space via acquisitions. For the treatment of cerebral aneurysms, Sequent has developed a novel device that combines the best attributes of embolization coils and flow diverters, its founders believe.

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC092164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel